Next anticipated Revita® clinical data readouts are 1-year data from the REVEAL-1 Cohort in Q2 2026 and 1-year randomized data from the REMAIN-1 ...

Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial Company ...

Soybean meal is the most economical source of protein for pigs, but the complex carbohydrates (stachyose, raffinose) and ...

Review authors suggested guidelines to help in standardizing future lupus nephritis studies. Heterogeneity in lupus nephritis (LN) trial design substantially hinders interpretation of studied drugs’ ...

Researchers at Carnegie Mellon University's School of Computer Science (SCS) revealed how small design changes in online tutoring platforms can help students push through their mistakes and keep ...

Use of genotype-guided SSRI shows no symptom improvement at 3 months in people with depression but is linked to higher ...

Passage Bio, which has been working toward a registrational trial for a drug candidate whose indications include ...

Operator: Ladies and gentlemen, thank you for joining, and welcome to the Innate Pharma First Quarter 2026 Business Update and Financial Results.

After some tough feedback from the FDA on the path forward for its lead gene therapy, Passage Bio has launched a strategic ...

Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement versus paclitaxel alone in the key secon ...

A phase 2 trial evaluated the efficacy of nivolumab added to brachytherapy, external beam radiation therapy, and ADT in men with high-risk grade group 5 prostate cancer.

Bank of America Global Healthcare Conference 2026 May 14, 2026 12:20 PM EDTCompany ParticipantsLara Weber - CFO ...